30 ACORN PARK DRIVE, CAMBRIDGE, MA
Parabilis Medicines Updates Guidance for ESMO Congress 2026 Presentation
CMO Departure - Fawzi Benzaghou Transitioning from Parabilis Medicines
Reports Second Quarter 2026 Financial Results and Provides Business Updates
Parabilis Medicines Enters Stock Purchase Agreement with Regeneron
Q2
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Amended Registration Statement for Securities
Certificate
Registration of Securities
S-1
No filings found
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Schedule 13D - Ownership Report
Free Writing Prospectus
S-1MEF
Amended Form D Notice of Exempt Offering of Securities